0.000USD0.000盘前交易 07/24, 09:30 (美东)
关键数据
43.030今开
43.505最高
1.91M成交量
12.06市盈率 TTM
8.47市盈率动
5.120股息TTM
0.08%换手率
43.790昨收
42.900最低
56.47M成交额
17.32市盈率静
1.24市净率
11.80%股息率 TTM
3.90%ROA
52.68052周最高
0.51量比
6.01B净利润
2.40B总股本
3.5959每股收益TTM
0.32Beta
6.87%ROE
42.32552周最低
1.38%振幅
67.33%毛利率
104.13B总市值
6.04回报/风险
0.98%风险率
操作建议
赛诺菲当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名53/155位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价56.27。中期看,股价处于平稳状态。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
收益预测
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
赛诺菲简介
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
公司代码SNY
公司赛诺菲
CEOHudson (Paul)
网址https://www.sanofi.com/
公司股东
常见问题
现在赛诺菲(SNY)的股票是买入、持有还是卖出?
根据分析师评级,赛诺菲(SNY)的总体评级为买入,目标价格为56.27。
赛诺菲(SNY)股票的每股收益(EPS TTM)是多少
赛诺菲(SNY)股票的每股收益(EPS TTM)是3.61。